Look to the people, products, and services of CooperVision.

CONTENTS





				:	SPHERI	E LENS	ES				
Product	Sphere Power (D)	Design	Wear Schedule	Material/ H₂0 Content	FDA Group	Base Curve (mm)	Dia (mm)	Oxygen Transmissibility DK/t**	Revenue Carton Size	Trials Labeled As / Pack Size	Features/ Design Technology
				1	-Day D	isposab	les				
clariti® 1 day sphere	+8.00 to -10.00 (0.50 steps after +/- 6.00) No Plano	Asphere	Daily wear	somofilcon A / 56%	5B SiHy	8.6	14.1	86	30-pack, 90-pack and 180-pack	56% 1 day Silicone Hydrogel sphere / 10pk	WetLoc* Technology UV blocking* Optimum modulus High oxygen transmissibility
MyDay® daily disposable	+8.00 to -12.00 (0.50 steps after +5.00 and -6.00) No Plano	Asphere	Daily wear	stenfilcon A / 54%	5B SiHy	8.4	14.2	100	90-pack and 180-pack	54% 1 day asphere / 5pk	 Aquaform® Technology Aberration Neutralizing System™ UV blocking* Optimum modulus High oxygen transmissibility
MyDay Energys®	+8.00 to -12.00 (0.50 steps after +5.00 and -6.00) No Plano	Asphere	Daily wear	stenfilcon A / 54%	5B SiHy	8.4	14.2	100	90-pack	54% 1 day asphere / 10pk	 Aquaform® Technology DigitalBoost™ Technology UV blocking* Optimum modulus High oxygen transmissibility
Proclear® 1 day	+8.00 to -12.00 (0.50 steps after +5.00 and -6.00) No Plano	Asphere	Daily wear	omafilcon A / 60%	2	8.7	14.2	28	90-pack	60% 1 day sphere / 10pk	Aberration Neutralizing System™ PC Technology™
MiSight® 1 day*	-0.50 to -7.00 (0.50 steps after -6.00) [†] No plano	Dual- focus	Daily wear	omafilcon A / 60%	2	8.7	14.2	28	90-pack and 180-pack	Myopia Management ActivControl™ Technology / 10pk	ActivControl® Technology Childhood myopia

^{*} WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. Persons should continue to use their protective UV-absorbing eyewear as directed.

©2025 CooperVision 17345-4 10/25 Page 2 of 8

NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of the outdoor activities). UV-absorbing contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-absorbing contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your Eye Care Practitioner for more information.

^{**(@-3.00}DS) x 10-9 [(cm/sec) x (ml O2)/(ml x mm Hg)].

[†] Treatment zones offer+2.00D of myopic defocus.

 $[\]pm$ Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8–12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism.

					SPHE	RE LEN	ISES					
Product	Sphere Power (D)	Design	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		Transmissibility	Revenue Carton Size	Trials Labeled As / Pack Size	Features/ Design Technology				
				2-We	ek Rep	olacem	ent Lei	nses				
Avaira Vitality Avaira Vitality Caugar Vision	+8.00 to -12.00 (0.50 steps after +/-6.00) No plano	Asphere	Daily wear	fanfilcon A / 55%	5B SiHy	8.4	14.2	112	6-pack	fanfilcon A / single	 Aberration Neutralizing System™ UV blocking* Optimum modulus High oxygen transmissibility 	
Biomedics® 55 Premier asphere†	-0.25 to -10.00 (0.50 steps after -6.00)			ocufilcon D /		8.6 8.9				ocufilcon D	 Aberration Neutralizing System[™] 	
Floreshier ST Francisco Graph Part ST Floreshier ST Flores	+0.25 to +8.00 (0.50 steps after +5.00)	Asphere	Daily wear	55%	4	8.8	14.2	26	6-pack	55% asphere / 3pk	• UV blocking*	
Monthly Replacement Lenses												
Biofinity®	+8.00 to -12.00 (0.50 steps after +/-6.00) No plano	Asphere	Daily Wear or Extended Wear up to 6 nights / 7 days	comfilcon A / 48%	5C SiHy	8.6	14.0	171	6-pack	comfilcon A / single	 Aquaform® Technology Aberration Neutralizing System™ Optimum modulus High oxygen transmissibility 	
Biofinity® XR	+8.50 to +15.00 -12.50 to -20.00 (0.50 steps)	Asphere	Daily Wear or Extended Wear up to 6 nights / 7 days	comfilcon A / 48%	5C SiHy	8.6	14.0	171	6-pack	comfilcon A XR / single	 Aquaform® Technology Aberration Neutralizing System™ Optimum modulus High oxygen transmissibility 	
Biofinity Energys Biofinity Energys Comprehens	+8.00 to -12.00 (0.50 steps after +/-6.00) No plano	Asphere	Daily Wear or Extended Wear up to 6 nights / 7 days	comfilcon A / 48%	5C SiHy	8.6	14.0	171	6-pack	Biofinity Energys®/ single	 Aquaform® Technology DigitalBoost™ Technology Optimum modulus High oxygen transmissibility 	
Proclear® sphere	+20.00 to -20.00 (0.50 steps after +/-6.00) No plano	Cohara	Daily	omafilcon B /	2	8.6	142	26	6 pools	Drocloss / 2x1	PC Tochnology [™]	
Colores and Colores Co	-0.25 to -10.00 (0.50 steps after -6.00)	Sphere	Daily wear	62%	2	8.2	14.2	36	6-pack	Proclear / 3pk	• PC Technology™	

^{*} WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. Persons should continue to use their protective UV-absorbing eyewear as directed

©2025 CooperVision 17345-4 10/25 Page 3 of 8

NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of the outdoor activities). UV-absorbing contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-absorbing contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your Eye Care Practitioner for more information.

^{**(@-3.00}DS) x 10-9 [(cm/sec) x (ml O2)/(ml x mm Hg)].

[†]Product being discontinued - diagnostic trials were discontinued on May 1, 2025. Revenue product orders may be placed through May 1, 2026.

						TORIC LE	NSES						
Product	Sphere Power (D)	Cylinder Power	Axis	Design	Wear Schedule	Material/ H₂0 Content	FDA Group	Base Curve (mm)	Dia (mm)	Oxygen Transmissibility DK/t**	Revenue Carton Size	Trials Labeled As / Pack Size	Features/ Design Technology
	1-Day Disposables												
clariti® 1 day toric	plano to -6.00	-0.75 -1.25 -1.75	Full circle in 10° steps										
	(0.25 steps)	-2.25	10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°, 170°, 180°										• WetLoc* Technology
	-6.50 to -9.00 (0.50 steps)	-0.75 -1.25 -1.75	10°, 20°, 60°, 70°, 80°, 90°, 100°, 110°, 120°, 160°, 170°, 180°	Toric	Daily wear	somofilcon A / 56%	5B SiHy	8.6	14.3	57	90-pack and 30-pack	56% 1 day Silicone Hydrogel toric / 5pk	UV blocking*Prism ballast designOptimum modulusHigh oxygen transmissibility
	(0.50 steps)	-2.25	10°, 20°, 90°, 160°, 170°, 180°										
	+0.25 to +4.00 (0.25 steps)	-0.75 -1.25 -1.75	10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°, 170°, 180°										
MyDay® toric	+8.00 to -10.00 (0.50 steps after -6.00)	-0.75 -1.25 -1.75 -2.25	Full circle in 10° steps	Toric	Daily wear	stenfilcon A / 54%	5B SiHy	8.6	14.5	80	90-pack	54% 1 day / Silicone Hydrogel toric / 5pk	 Aquaform® Technology Optimized Toric Lens Geometry™ UV blocking* Optimum modulus High oxygen transmissibility

©2025 CooperVision 17345-4 10/25 Page 4 of 8

^{*} WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. Persons should continue to use their protective UV-absorbing eyewear as directed.

NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of the outdoor activities). UV-absorbing contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-absorbing contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your Eye Care Practitioner for more information.

^{**(@-3.00}DS) x 10-9 [(cm/sec) x (ml O2)/(ml x mm Hg)].

	TORIC LENSES													
Product	Sphere Power (D)	Cylinder Power	Axis	Design	Wear Schedule	Material/ H ₂ 0 Content	FDA Group	Base Curve (mm)	Dia (mm)	Oxygen Transmissibility DK/t**	Revenue Carton Size	Trials Labeled As / Pack Size	Features/ Design Technology	
2-Week Replacement Lenses														
Avaira Vitality® toric	+8.00 to -10.00 (0.50 steps after +/-6.00)	-0.75 -1.25 -1.75 -2.25	Full circle in 10° steps	Toric	Daily wear	fanfilcon A / 55%	5B SiHy	8.5	14.5	90	6-pack	fanfilcon A / single	 Optimized Toric Lens Geometry™ UV blocking* Optimum modulus High oxygen transmissibility 	
Biomedics® toric†	+6.00 to -10.00 (0.50 steps after -6.00 and +5.00)	-0.75 -1.25 -1.75 -2.25	Full circle in 10° steps	Toric	Daily wear	ocufilcon D / 55%	4	8.7	14.5	18	6-pack	ocufilcon D toric / single	• UV blocking*	

©2025 CooperVision 17345-4 10/25

^{*} WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. Persons should continue to use their protective UV-absorbing eyewear as directed.

NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of the outdoor activities). UV-absorbing contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-absorbing contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your Eye Care Practitioner for more information.

^{**(@-3.00}DS) x 10-9 [(cm/sec) x (ml O2)/(ml x mm Hg)].

[†]Product being discontinued - diagnostic trials were discontinued on May 1, 2025. Revenue product orders may be placed through May 1, 2026.

					TC	RIC LENS	ES						
Product	Sphere Power (D)	Cylinder Power	Axis	Design	Wear Schedule	Material/ H₂0 Content	FDA Group	Base Curve (mm)	Dia (mm)	Oxygen Transmissibility DK/t**	Revenue Carton Size	Trials Labeled As / Pack Size	Features/ Design Technology
					Monthly I	Replaceme	nt Ler	ises					
Biofinity® toric	+8.00 to -10.00 (0.50 steps after +/-6.00)	-0.75 -1.25 -1.75 -2.25	Full circle in 10° steps	Toric	Daily wear or extended wear 7 days / 6 nights	comfilcon A / 48%	5C SiHy	8.7	14.5	116	6-pack	comfilcon A toric / single	 Aquaform® Technology Optimized Toric Lens Geometry™ Optimum modulus High oxygen transmissibility
Biofinity® XR toric	+8.50 to +20.00 and -10.50 to -20.00 (0.50 steps)	-0.75 -1.25 -1.75 -2.25											• Aquaform® Technology
total Caperhary	+20.00 to -20.00 (0.50 steps after +/-6.00)	-2.75 -3.25 -3.75 -4.25 -4.75 -5.25 -5.75	Full circle in 5° steps	Toric	Daily wear or extended wear 7 days / 6 nights	comfilcon A / 48%	5C SiHy	8.7	14.5	116	6-pack	comfilcon A toric / single	 Optimized Toric Lens Geometry™ Optimum modulus High oxygen transmissibility
Proclear® toric	+6.00 to -8.00 (0.50 steps after -6.50)	-0.75 -1.25 -1.75 -2.25	Full circle in 10° steps	Toric	Daily wear	omafilcon B /	2	8.8	14.4	19.4 (MTO) 23.7 (Moulded) 16 (MTO)	6-pack	Proclear® toric / single	• PC Technology™
Proclear® XR toric*	+6.25 to +10.00 (0.50 steps after +6.50) -8.50 to -10.00 (0.50 steps)	-0.75 -1.25 -1.75 -2.25	Full circle in			omafilcon B /		8.8		13.9		Proclear® toric /	
and the second	+10.00 to -10.00 (0.50 steps after +/-6.50)	-2.75 to -5.75 (0.50D steps)	5° steps	Toric	Daily wear	62%	2	8.4	14.4	10.4	6-pack	single	• PC Technology™

^{*}Product being discontinued – diagnostic trials were discontinued on November 1, 2025. Revenue product orders may be placed through November 1, 2026. **(@-3.00DS) x 10-9 [(cm/sec) x (ml O2)/(ml x mm Hg)].

Page 6 of 8 ©2025 CooperVision 17345-4 10/25

MULTIFOCAL LENSES													
Product	Sphere Power (D)	ADD Power	Design	Wear Schedule	Material/ H ₂ 0 Content	FDA Group	Base Curve (mm)	Dia (mm)	Oxygen Transmissibility DK/t**	Revenue Carton Size	Trials Labeled As / Pack Size	Features/ Design Technology	
					1-Day Disp	osabl	es						
clariti® 1 day multifocal†	+5.00 to -6.00 in 0.25 steps	Low: Up to +1.25 High: +1.50 to +2.25	Multifocal	Daily wear	somofilcon A / 56%	5B SiHy	8.6	14.1	86	90-pack and 30-pack	56% 1 day Silicone Hydrogel multifocal / 10pk	 WetLoc* Technology UV blocking* Optimum modulus High oxygen transmissibility 	
clariti® 1 day multifocal 3 Add	+8.00 to -10.00 (0.25 steps) -10.50 to -12.00 (0.50 steps)	Low: +0.75D to +1.25D Med: +1.50D to +1.75D High: +2.00D to +2.50D	Multifocal	Daily wear	somofilcon A / 56%	5B SiHy	8.6	14.1	86	90-pack and 30-pack	Somofilcon A 1 day / 10pk	 WetLoc® Technology Binocular Progressive System™ UV blocking* Optimum modulus High oxygen transmissibility 	
MyDay® multifocal	+8.00 to -10.00 (0.25 steps) -10.50 to -12.00 (0.50 steps)	Low: +0.75D to +1.25D Med: +1.50D to +1.75D High: +2.00D to +2.50D	Multifocal	Daily wear	stenfilcon A / 54%	5B SiHy	8.4	14.2	100	90-pack	54% 1 day Silicone Hydrogel multifocal / 10pk	 Aquaform® Technology Binocular Progressive System™ UV blocking* Optimum modulus High oxygen transmissibility 	
Proclear® 1 day multifocal	+6.00 to -10.00 (0.50 steps after -6.00)	Single power profile	Multifocal	Daily wear	omafilcon A / 60%	2	8.7	14.2	28	90-pack	60% 1 day PC multifocal / 10pk	• PC Technology™	
				Mon	thly Replac	ement	Lens	es					
Biofinity® multifocal	+6.00 to -10.00 (0.50 steps after -6.00)	+1.00 +1.50 +2.00 +2.50	Multifocal D Lens N Lens	Daily wear or extended wear 7 days/6 nights	comfilcon A / 48%	5C SiHy	8.6	14.0	142	6-pack	comfilcon A multifocal / single	 Aquaform® Technology Balanced Progressive® Technology Optimum modulus High oxygen transmissibility 	
Proclear® multifocal	+6.00 to -8.00 (0.50 steps after -6.50)	+1.00 +1.50 +2.00 +2.50	Multifocal D Lens N Lens	Daily wear	omafilcon B / 62%	2	8.7	14.4	14	6-pack	Proclear® multifocal / single	• PC Technology™	

^{*} WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. Persons should continue to use their protective UV-absorbing eyewear as directed.

©2025 CooperVision 17345-4 10/25 Page 7 of 8

NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of the outdoor activities). UV-absorbing contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-absorbing contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your Eye Care Practitioner for more information.

^{**(@-3.00}DS) x 10-9 [(cm/sec) x (ml O2)/(ml x mm Hg)].

[†] Product being discontinued - diagnostic trials were discontinued on June 30, 2025. Revenue product orders may be placed through October 31, 2026.

				MULTIF	OCAL LEN	SES						
Product	Sphere Power (D)	ADD Power	Design	Wear Schedule	Material/ H ₂ 0 Content	FDA Group	Base Curve (mm)	Dia (mm)	Oxygen Transmissibility DK/t**	Revenue Carton Size		L Design Technology
Monthly Replacement Lenses												
Proclear®XR multifocal*	+6.25 to +20.00 -8.50 to -20.00 (0.50 steps after +/-6.50)	+1.00 +1.50 +2.00 +2.50					8.7		From: 14.0			
Product III Copportuni	+20.00 to -20.00 (0.50 steps after +/- 6.50)	+3.00 +3.50 +4.00	Multifocal D Lens N Lens	Daily wear	omafilcon B / 62%	2		14.4	(-3.00D/+4.00D, N type) To: 16.7	6-pack	Proclear multifocal / single	• PC Technology™
iach.	+20.00 to -20.00 (0.50 steps after +/- 6.50)	+1.00 +1.50 +2.00 +2.50 +3.00 +3.50 +4.00					8.4		(-3.00/+2.50D, D Type)			

	TORIC MULTIFOCAL LENSES													
Product	Sphere Power (D)	Cylinder Power	Axis	ADD Power	Design	Wear Schedule	Material/ H₂0 Content	FDA Group	Base Curve (mm)	Dia (mm)	Oxygen Transmissibility DK/t**	Revenue Carton Size	Trials Labeled As / Pack Size	Features/ Design Technology
Monthly Replacement Lenses														
Biofinity® toric multifocal	+10.00 to -10.00 (0.50 steps after +/-6.00)	-0.75 to -5.75 (0.50D steps)		+1.00 +1.50 +2.00 +2.50	Toric Multifocal D Lens N Lens	Daily wear or extended wear 7 days /6 nights	comfilcon A / 48%	5C SiHy	8.7	14.5	116	6-pack	Biofinity® toric multifocal / single	 Aquaform® Technology Optimized Toric Lens Geometry™ Balanced Progressive® Technology Optimum modulus High oxygen transmissibility
Proclear® multifocal toric*	+20.00 to -20.00 (0.50 steps after +/-6.50)	-0.75 to -5.75 (0.50D steps)		+1.00 to +4.00 (0.50D steps)	Toric Multifocal D Lens N Lens	Daily wear	omafilcon B / 62%	2	8.8 8.4	14.4	From 14.5 (-3.00D/+4.00D, N Type) To 17.7 (-3.00D/+4.00D, D Type)	6-pack	Proclear® multifocal toric / single	• PC Technology™

^{*}Product being discontinued – diagnostic trials were discontinued on November 1, 2025. Revenue product orders may be placed through November 1, 2026. **(@-3.00DS) x 10-9 [(cm/sec) x (ml 02)/(ml x mm Hg)].

©2025 CooperVision 17345-4 10/25 Page 8 of 8